# Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

> **NCT03422822** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 3166 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Abrocitinib 100 mg
- **DRUG:** Abrocitinib 200 mg
- **DRUG:** Placebo
- **DRUG:** Abrocitinib 100 mg
- **DRUG:** Abrocitinib 100 mg
- **DRUG:** Abrocitinib 200 mg

## Key facts

- **NCT ID:** NCT03422822
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-08
- **Primary completion:** 2025-12-22
- **Final completion:** 2025-12-22
- **Target enrollment:** 3166 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03422822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03422822, "Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03422822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*